ArticleIBRO neuroscience reports2026
Frankincense improves motor symptoms and attenuates the progression of Paraquat (PQ)-induced Parkinson's disease in mice by attenuating oxidative stress, inflammation, and apoptotic cell death and improving nerve growth factor gene expression.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Chronic Paraquat Neurotoxicity and Dopaminergic Degeneration: A Mechanistic Review.Chemistry & biodiversity · 2026Review
- Primary prevention of Parkinson's disease: proceedings, the 8C's and a position statement from the Parkinson's disease prevention think tank.NPJ Parkinson's disease · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The purpose of the present investigation is to examine the neuroprotective impact of frankincense at different concentrations (10, 20, and 50 mg/kg/day) and discover its potential mechanisms associated with oxidative stress and apoptosis. To cause Parkinson's disease (PD) in mice, Paraquat (PQ) was dissolved in 0.9 % normal saline (10 mg/kg, i.p.) and administrated twice a week for three weeks. The mice were randomly divided into five cohorts ( n = 10): i) control (CON), ii) PQ (vehicle), iii) PQ + Frankincense (10 mg/kg), (iv) PQ + Frankincense (20 mg/kg), (v) PQ + Frankincense (50 mg/kg). We evaluated the effects of PQ and frankincense on behaviors using the open field test (OFT), rotarod performance test, forced swim test, and bar test. Oxidative stress factors, inflammatory markers, dopamine levels, acetylcholinesterase (AChE) activity, and apoptotic markers were assessed using ELISA and qPCR, respectively. PQ treatment caused abnormalities in motor coordination in the rotarod test, spontaneous motor activity in OFT, duration of immobility time in the forced swim test, and increased oxidative stress and apoptosis by elevating MDA level, mRNA levels of caspase3, and reducing mRNA levels of Bcl-2 and NGF. PQ treatment also reduced dopamine levels and increased AChE activity. Treatment with frankincense at different concentrations (10, 20, and 50 mg/kg/day) improved motor symptoms by inhibiting oxidative stress, inflammation, and apoptosis and elevation of dopamine levels and NGF gene expression in a dose dependent manner. In sum, frankincense exerted an inhibitory impact on the progression of PQ-induced PD model in mice by mitigating oxidative stress, neuroinflammation, and apoptotic cell death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.